A Chimeric Peptide Composed of a Dermaseptin Derivative and an RNA III-Inhibiting Peptide Prevents Graft-Associated Infections by Antibiotic-Resistant Staphylococci

Naomi Balaban,1* Yael Gov,1 Andrea Giacometti,2 Oscar Cirioni,2 Roberto Ghiselli,3 Federico Mochegianii,3 Fiorenza Orlando,4 Giuseppina D’Amato,2 Vittorio Saba,3 Giorgio Scalise,2 Sabina Bernes,5 and Amram Mor5*

Department of Human Microbiology, Sackler School of Medicine, Tel Aviv University, Tel Aviv,1 and Laboratory of Antimicrobial Peptides Investigation, Department of Food Engineering & Biotechnology, Technion-Israel Institute of Technology, Haifa 32000.3 Israel, and Institute of Infectious Diseases and Public Health2 and Department of General Surgery, I.N.R.C.A., I.R.R.C.S.,3 University of Ancona, and Research Department, Biotechnology Center, I.N.R.C.A., I.R.R.C.S.,4 Ancona, Italy

Received 2 May 2003/Returned for modification 6 October 2003/Accepted 24 December 2003

Staphylococcal bacteria are a prevalent cause of infections associated with foreign bodies and indwelling medical devices. Bacteria are capable of escaping antibiotic treatment through encapsulation into biofilms. RNA III-inhibiting peptide (RIP) is a heptapeptide that inhibits staphylococcal biofilm formation by obstructing quorum-sensing mechanisms. K5-S4(1-13), is a 13-residue dermaseptin derivative (DD13) believed to kill bacteria via membrane disruption. We tested each of these peptides as well as a hybrid construct, DD13-RIP, for their ability to inhibit bacterial proliferation and suppress quorum sensing in vitro and for their efficacy in preventing staphylococcal infection in a rat graft infection model with methicillin-resistant Staphylococcus aureus (MRSA) or S. epidermidis (MRSE). In vitro, proliferation assays demonstrated that RIP had no inhibitory effect, while DD13-RIP and DD13 were equally effective, and that the chimeric peptide but not DD13 was slightly more effective than RIP in inhibiting RNA III synthesis, a regulatory RNA molecule important for staphylococcal pathogenesis. In vivo, the three peptides reduced graft-associated bacterial load in a dose-dependent manner, but the hybrid peptide was most potent in totally preventing staphylococcal infections at the lowest dose. In addition, each of the peptides acted synergistically with antibiotics. The data indicate that RIP and DD13 act in synergy by attacking bacteria simultaneously by two different mechanisms. Such a chimeric peptide may be useful for coating medical devices to prevent drug-resistant staphylococcal infections.

RIP inhibits pathogenesis via biofilm formation (6) and toxin production (73) by disrupting quorum-sensing mechanisms through inhibition of TRAP phosphorylation (4). TRAP is a protein unique to staphylococci but is highly conserved among strains, and therefore its inhibitor RIP was effective against any staphylococcal strain tested (2, 3, 14, 27, 29, 73). RIP does not directly kill the bacteria but interferes with their signal transduction, thus making them nonpathogenic.

The ubiquitously produced cationic antimicrobial peptides (1, 9, 23, 30, 31, 39, 57, 72) are attracting increasing research and clinical interest for their roles in innate immunity and for their potential uses in various antimicrobial fields (50, 74). The cytoplasmic membrane was proposed to be their ultimate target. Being cationic, the peptides interact electrostatically with the negatively charged phospholipid headgroups and insert into the membrane bilayer in a manner that leads to its disruption (22, 33, 35, 42, 65). Although the steps involved in this

* Corresponding author. Mailing address: Amram Mor, Laboratory of Antimicrobial Peptides Investigation, Department of Food Engineering & Biotechnology, Technion-Israel Institute of Technology, Haifa 32000, Israel. Phone: (972) 4-829-3340, Fax: (972) 4-832-0742. E-mail: amor@tx.technion.ac.il. Naomi Balaban, Department of Human Microbiology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Phone: (972) 3-640-5137. E-mail: naomibalaban@yahoo.com.

Nosocomial infections due to Staphylococcus aureus and Staphylococcus epidermidis have increased over the last decades (36, 41, 42). These common skin bacteria are also known to be a frequent cause of infections related to prosthetic and indwelling medical devices (16, 46), where these infections are described to suppress diseases caused by S. aureus and S. epidermidis (2–6, 14, 27, 29, 73). RIP does not inhibit the late-appearing vascular graft infections are one of the most feared complications that the vascular surgeon treats, frequently resulting in prolonged hospitalization, organ failure, amputation, and death (7, 34).

Effective strategies for the prevention of prosthetic infections vary and include the use of antimicrobials bound in high concentrations to prosthetic grafts (11, 44, 63, 69, 71). Because of the increase in resistance to antibiotics, several studies have focused on developing new antimicrobial materials that reduce biofilm formation (28, 71). One of the most interesting studies was based on the fact that the resistance of a biofilm to antibiotic-resistant staphylococci is acquired as a multicellular strategy that relies on exchange of chemical signals between cells in a process known as quorum sensing (48). Thus, interfering with this mechanism of bacterial cell-cell communication could provide a novel approach to prevent biofilm formation. A seven-amino acid peptide termed the RNA III-inhibiting peptide (RIP) was described to suppress diseases caused by S. aureus and S. epidermidis (2–6, 14, 27, 29, 73).

RIP inhibits pathogenesis via biofilm formation (6) and toxin production (73) by disrupting quorum-sensing mechanisms through inhibition of TRAP phosphorylation (4). TRAP is a protein unique to staphylococci but is highly conserved among strains, and therefore its inhibitor RIP was effective against any staphylococcal strain tested (2, 3, 14, 27, 29, 73). RIP does not directly kill the bacteria but interferes with their signal transduction, thus making them nonpathogenic.

The ubiquitously produced cationic antimicrobial peptides (1, 9, 23, 30, 31, 39, 57, 72) are attracting increasing research and clinical interest for their roles in innate immunity and for their potential uses in various antimicrobial fields (50, 74). The cytoplasmic membrane was proposed to be their ultimate target. Being cationic, the peptides interact electrostatically with the negatively charged phospholipid headgroups and insert into the membrane bilayer in a manner that leads to its disruption (22, 33, 35, 42, 65). Although the steps involved in this
mechanism remain to be delineated, there is a large body of experimental data demonstrating that antimicrobial peptides display a direct correlation between antibiotic effect and increased plasma membrane permeability, conductance of ions across lipid bilayers, and dissipation of the transmembrane electric potential (17, 21, 24, 39, 49, 58, 59, 62, 68, 66). Thus, while their precise mechanism of action is not fully understood, their microbicidal effect is believed to result from the peptides’ capacity to disrupt the ordered membrane structure of target cells.

The molecular basis for selective activity between mammalian and bacterial cells is also ill defined but is believed to result from differences in the lipid composition of target versus non-target cells, such as membrane fluidity and high negative charge density (1, 12, 45, 74). These differences seem to be responsible for the preferred accumulation of antimicrobial peptides on microbial membranes. Numerous studies have demonstrated that the peptides’ physicochemical properties, i.e., amphipathy, positive charge content, and hydrophobicity, are the main factors affecting membrane lysis activity (1, 8, 12, 42). Accordingly, isomers composed of all D-amino acids are as active as the L-enantiomers, implying that the mechanism of action is not mediated by interaction with a stereo-specific receptor. These properties enabled several cationic antimicrobial peptides to escape microbial mechanisms involved in multidrug resistance (12, 25, 56).

Dermaseptins are a large family of linear polycationic peptides from frog skin (10, 51, 53, 54) whose cytolytic activity is believed to result from interaction of their N-terminal domain with the plasma membranes of target cells (52, 55). Recent investigations with respect to the relations between physical properties (structure and organization in solution) of dermaseptin S4 and its interaction with target membranes (19, 37) led to the design of short derivatives that maintain the amphipathic alpha-helical structure of the parent peptide, bind avidly to membrane models with association affinity constants \( K_f \) in the range of \( 10^5 \) to \( 10^7 \) M\(^{-1}\) and exert rapid cytolytic activity against a variety of pathogens. Among these, the 13-mer derivative \( K_r \cdot S4\cdot(1\text{-}13) \) is of particular interest as it is the smallest derivative that combines low toxicity and efficient large-spectrum antimicrobial activity both in culture and in animal models of infection (20, 56).

In this paper, we tested the hypothesis that a hybrid construct composed of RIP and dermaseptin would benefit from the properties of both components. We show that RIP and the 13-mer dermaseptin derivative DD\(_{13}\) individually inhibit biofilm formation on a Dacron graft and that their chimeric version eradicates drug-resistant staphylococcal infections in a fashion that is greater than the additive effect of the individual peptides comprising the chimera.

**MATERIALS AND METHODS**

**Peptides** Peptides were synthesized by the solid-phase method as described previously (37), applying the Fmoc active ester chemistry on a fully automated, programmable model 433A peptide synthesizer (Applied Biosystems). 4-Methylbenzhydramine-resin (Novabiochem) was used to obtain amidated peptides. The crude peptides were extracted from the resin with 30% acetonitrile in water and purified to chromatographic homogeneity in the range of 98 to >99% by reverse-phase high-pressure liquid chromatography (HPLC) (Alliance-Waters). HPLC runs were performed on a semipreparative C4 column (Yvadac) with a linear gradient of acetonitrile in water (1%/min), both solvents containing 0.1% trifluoroacetic acid. The purified peptides were subjected to amino acid analysis and electrospray mass spectrometry in order to confirm their composition. Peptides were stored as a lyophilized powder at \(-20^\circ\text{C}\).

**CD spectra** Circular dichroism (CD) spectra were measured in 20% (v/v) trifluoroethanol in water with an AVIV model 202 DS spectrometer (Aviv Assoc., Lakewood, N.J.) with a 0.02-cm rectangular Q5 Hellma cuvette at 25°C. CD data represent average values from three separate recordings.

**Bacteria** Methicillin-resistant \( S. aureus \) (MRSA) strain ATCC 43300 was commercially purchased from Oxoid S.p.A., Milan, Italy. Methicillin-resistant \( S. epidermidis \) (MRSE) was a clinical strain from the Institute of Infectious Diseases and Public Health, University, Italy.

**Animals** Adult male Wistar rats, 250 to 300 g (Istituto Nazionale Riposo e Cura Anziani, Istituto di Ricerco e Cura a Carattere Scientifico animal facility, Ancona, Italy) were used, with 15 animals per experimental group.

**Susceptibility testing** The antimicrobial susceptibilities of the strains were determined by the broth microdilution method, according to the procedures outlined by the National Committee for Clinical Laboratory Standards. The MIC was taken as the lowest antibiotic concentration at which observable growth was inhibited. Experiments were performed in triplicate.

**Graft infection rat model** Rats were anesthetized, their back hair was shaved, and the skin was cleaned with 10% povidone-iodine solution. One subcutaneous pocket was made on each side of the median line by a 1.5-cm incision. Aseptically, 1-cm\(^2\) sterile albumin-seeded Dacron grafts (Aliborgraft; Sorin Biomedica Cardio, S.p.A., Saluggia VC, Italy) were implanted into the pockets. Before implantation, the grafts were soaked for 20 min in sterile solutions of the various agents. The pockets were closed by means of skin clips, and saline solution (1 ml) containing MRSA or MRSE at a concentration of \( 2 \times 10^7 \) CFU/ml was inoculated onto the graft surface with a tuberculin syringe to create a subcutaneous fluid-filled pocket. The animals were returned to individual cages and thoroughly examined daily. All grafts were explanted at 7 days following implantation.

**Assessment of the infection** The explanted grafts were placed in sterile tubes, washed in sterile saline solution, placed in tubes containing 10 ml of phosphate-buffered saline solution, and sonicated for 5 min to remove the adherent bacteria from the grafts (6). After sonication, grafts were microscopically checked to verify that all bacteria were removed. Quantitation of viable bacteria was performed by culturing serial dilutions (0.1 ml) of the bacterial suspension on blood agar plates. All plates were incubated at 37°C for 48 h and evaluated for the presence of the staphylococcal strains. The organisms were quantitated by counting the number of CFU per plate. No significant differences in cell viability were present upon testing the effect of sonication for up to 10 min on both antibiotic-sensitive and -resistant bacteria. The limit of detection for this method was approximately 10 CFU/ml (14).

**Peptide binding to Dacron** To determine how much peptide impregnated the graft, 1-cm\(^2\) slices of collagen-sealed Dacron were soaked at room temperature in peptide solutions in quadruplicate for 0.5 and 3 h (1 ml of saline per graft, containing 50 \( \mu \)g/ml of each peptide). Following the incubation period, the Dacron was removed, and residual peptide (unbound fraction) was subjected to reverse-phase HPLC analysis as described above. Peptide identification was based on retention time and spectral analysis. The amount of unbound peptide was calculated by area integration of the UV-absorbing peak (220 nm) and comparison with standard curves of known concentrations for each peptide (19).

**RNA III synthesis and bacterial growth** Early-exponential-phase \( S. aureus \) cells containing the mraii-blaz fusion construct (29) were grown in 30 \( \mu \)l (2 \( \times \) 10\(^7\) cells) for 2.5 h with 5 \( \mu \)l of peptides (0 to 5 \( \mu \)g) in TSB growth medium at 37°C with shaking. Of the total reaction volume (35 \( \mu \)l), a 5-\( \mu \)l sample was removed, diluted in saline, and streaked on Luria agar plates to determine CFU. The rest of the reaction mixture was used to determine RNA III synthesis (beta-lactamase activity). This was done by adding the 1:100 dilution of beta-lactamase (nitrocefin), and the optical density (OD) was determined at 490 and 650 nm (29).

**Statistical analysis** MICs are presented as the geometric mean of three separate experiments. Quantitative culture results from all groups are presented as mean ± standard deviation, and the statistical comparisons between groups were made with analysis of variance on the log-transformed data. Significance was accepted when the \( P \) value was ≤0.05.

**RESULTS**

**Prevention of graft-associated infections** Since DD\(_{13}\) is a bactericidal peptide while RIP prevents staphylococcal biofilm formation, a hybrid version, DD\(_{13}\)-RIP, was constructed (Table 1) and tested for efficacy in preventing staphylococcal graft-
TABLE 1. Primary structures and designations of the peptides investigated

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Amino acid sequence</th>
<th>Designation</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIP</td>
<td>YSPWTNF&lt;sub&gt;H11003&lt;/sub&gt;</td>
<td>RIP</td>
</tr>
<tr>
<td>K&lt;sub&gt;H11003&lt;/sub&gt;-S4(1–13)</td>
<td>ALWKTLKKVLA&lt;sub&gt;H11003&lt;/sub&gt;</td>
<td>DD&lt;sub&gt;H11003&lt;/sub&gt;</td>
</tr>
<tr>
<td>Hybrid</td>
<td>ALWKTLKKVLA&lt;sub&gt;H11003&lt;/sub&gt;YSPWTNF&lt;sub&gt;H11003&lt;/sub&gt;</td>
<td>DD&lt;sub&gt;H11003&lt;/sub&gt;–RIP</td>
</tr>
</tbody>
</table>

associated infections. The RIP and DD<sub>13</sub> concentrations range to be tested was based on their active concentrations from previous studies (2–6, 19, 20, 22, 37, 56). Immediately prior to being implanted in rats, the collagen-coated Dacron grafts were coated with 10, 20, or 50 mg of either RIP or DD<sub>13</sub> per liter and compared to DD<sub>13</sub>–RIP at the same concentrations.

Bacteria (MRSA or MRSE) were injected into the implants, the implants were removed after a week, and the bacterial load was determined. The study included a negative control group (untreated graft with no bacterial challenge) and a positive control group (untreated graft with bacterial challenge). The results are summarized in Table 2. None of the animals included in the negative control group had anatomic or microbiological evidence of graft infection (no graft contamination).

All rats included in the positive control groups that were implanted with untreated grafts and challenged with MRSA or MRSE (total of 30 rats) demonstrated evidence of bacterial colonization, with quantitative results showing 4.4 × 10<sup>10</sup> ± 1.2 × 10<sup>10</sup> and 6.9 × 10<sup>10</sup> ± 1.8 × 10<sup>10</sup> CFU/ml, respectively, and those challenged with MRSE demonstrated reduced evidence of infection with 6.9 × 10<sup>10</sup> ± 1.9 × 10<sup>10</sup> and 8.5 × 10<sup>10</sup> ± 2.0 × 10<sup>10</sup> CFU/ml, respectively.

Animals implanted with grafts presoaked in 10, 20, or 50 mg of RIP solutions per liter and challenged with MRSA demonstrated reduced evidence of bacterial colonization, with 4.1 × 10<sup>10</sup> ± 7.1 × 10<sup>9</sup>, 5.9 × 10<sup>10</sup> ± 1.7 × 10<sup>10</sup>, and 8.4 × 10<sup>10</sup> ± 3.6 × 10<sup>10</sup> CFU/ml, respectively, and those challenged with MRSE demonstrated reduced evidence of infection with 6.9 × 10<sup>10</sup> ± 1.9 × 10<sup>10</sup>, 8.5 × 10<sup>10</sup> ± 2.0 × 10<sup>10</sup>, and 3.9 × 10<sup>11</sup> ± 1.6 × 10<sup>11</sup> CFU/ml, respectively.

Animals implanted with grafts presoaked with DD<sub>13</sub> and challenged with MRSA demonstrated reduced evidence of bacterial colonization, with 5.8 × 10<sup>12</sup> ± 1.6 × 10<sup>12</sup> and 4.0 × 10<sup>12</sup> ± 1.7 × 10<sup>12</sup> CFU/ml, respectively, and negative quantitative cultures for the same doses as RIP. Similarly, animals challenged with MRSE demonstrated reduced or no evidence of infection, with 5.2 × 10<sup>2</sup> ± 1.6 × 10<sup>2</sup> and 4.4 × 10<sup>3</sup> ± 1.3 × 10<sup>3</sup> CFU/ml, respectively, and negative quantitative cultures.

Animals implanted with DD<sub>13</sub>–RIP solutions and challenged with MRSA demonstrated reduced evidence of bacterial colonization, with 1.9 × 10<sup>3</sup> ± 0.3 × 10<sup>3</sup> CFU/ml at 10 mg per liter and when the grafts were soaked in 20 or 50 mg per liter, animals showed no evidence of staphylococcal infection, with negative quantitative cultures. Similarly, animals challenged with MRSE displayed 3.0 × 10<sup>10</sup> ± 0.7 × 10<sup>10</sup> CFU/ml and negative quantitative cultures for 10 and 20 to 50 mg per liter.

In addition, treatment with these peptides was compared with the conventionally used antibiotic rifampin (63). These experimental groups received grafts presoaked with 5 mg of rifampin per liter alone or rifampin and RIP, DD<sub>13</sub>, or DD<sub>13</sub>–RIP at 10 mg per liter. The results are summarized in Table 3. The group of rifampin-treated rats showed quantitative culture results of 6.7 × 10<sup>1</sup> ± 9.1 × 10<sup>2</sup> CFU/ml for MRSA and 8.8 × 10<sup>2</sup> ± 3.0 × 10<sup>2</sup> CFU/ml for MRSE, but when grafts were soaked in combination with RIP, DD<sub>13</sub>, or DD<sub>13</sub>–RIP, the animals showed negative quantitative cultures and no evidence of bacterial colonization. Note that rifampin-resistant bacteria that were exposed to DD<sub>13</sub> were previously shown to exhibit a MIC identical to that obtained with rifampin-sensitive bacteria (56).

Of note is that all agents used did not show any signs of toxicity and none of the animals included in any group died or had clinical evidence of drug-related adverse effects, such as local signs of perigraft inflammation, anorexia, vomiting, diarrhea, or behavioral alterations. Reduction in bacterial load was significant (P < 0.05) in all experimental groups compared to positive control groups.

In vitro studies. (i) Peptide binding to Dacron cuffs. To verify the relationships between the observed in vivo activity and the amount of peptide present on the Dacron grafts, the grafts were soaked in peptide solutions as described above prior to being grafted in rats. After removal of the grafts, the solutions were subjected to HPLC analysis, from which the amount of Dacron-bound peptide was deduced from the calculated amount of residual unbound fraction. The results are summarized in Fig. 1 for the peptide solution of 50 mg per liter. Among the three peptides, RIP bound the least, with a mean bound amount of 6.5 ± 2.5 μg/cm². DD<sub>13</sub> was found to bind the most and significantly more than RIP, with a mean

TABLE 2. Effect of peptides on graft-associated infections in rats

<table>
<thead>
<tr>
<th>Treatment&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Soaking solution (mg/liter)</th>
<th>MRSA (mean CFU/ml ± SD)</th>
<th>MRSE (mean CFU/ml ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None (control)</td>
<td>0</td>
<td>4.4 × 10&lt;sup&gt;9&lt;/sup&gt; ± 1.2 × 10&lt;sup&gt;9&lt;/sup&gt;</td>
<td>6.9 × 10&lt;sup&gt;10&lt;/sup&gt; ± 1.8 × 10&lt;sup&gt;10&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>4.1 × 10&lt;sup&gt;9&lt;/sup&gt; ± 7.1 × 10&lt;sup&gt;8&lt;/sup&gt;</td>
<td>6.9 × 10&lt;sup&gt;9&lt;/sup&gt; ± 1.9 × 10&lt;sup&gt;9&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>5.9 × 10&lt;sup&gt;9&lt;/sup&gt; ± 1.7 × 10&lt;sup&gt;9&lt;/sup&gt;</td>
<td>8.5 × 10&lt;sup&gt;9&lt;/sup&gt; ± 2.0 × 10&lt;sup&gt;9&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>84 ± 36</td>
<td>39 ± 16</td>
</tr>
<tr>
<td>RIP&lt;sup&gt;b&lt;/sup&gt;</td>
<td>10</td>
<td>5.8 × 10&lt;sup&gt;9&lt;/sup&gt; ± 2.1 × 10&lt;sup&gt;9&lt;/sup&gt;</td>
<td>5.2 × 10&lt;sup&gt;9&lt;/sup&gt; ± 2.0 × 10&lt;sup&gt;9&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>40 ± 17</td>
<td>44 ± 15</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>&lt;10</td>
<td>&lt;10</td>
</tr>
<tr>
<td>DD&lt;sub&gt;13&lt;/sub&gt;&lt;sup&gt;b&lt;/sup&gt;</td>
<td>10</td>
<td>19 ± 3</td>
<td>30 ± 7</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>&lt;10</td>
<td>&lt;10</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>&lt;10</td>
<td>&lt;10</td>
</tr>
<tr>
<td>DD&lt;sub&gt;13&lt;/sub&gt;–RIP&lt;sup&gt;b&lt;/sup&gt;</td>
<td>10</td>
<td>19 ± 3</td>
<td>30 ± 7</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>&lt;10</td>
<td>&lt;10</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>&lt;10</td>
<td>&lt;10</td>
</tr>
</tbody>
</table>

<sup>a</sup> Dacron grafts were presoaked in saline (control), RIP, DD<sub>13</sub>, or DD<sub>13</sub>–RIP at the designated concentrations and implanted in rats (15 rats per group). Grafts were then incubated with MRSA or a clinical isolate of MRSE. Grafts were removed after a week, and CFU were determined. *, P < 0.05 compared to control untreated group.

TABLE 3. Prevention of graft-associated infections in rats based on combined therapy<sup>a</sup>

<table>
<thead>
<tr>
<th>Treatment</th>
<th>MRSA (mean CFU/ml ± SD)</th>
<th>MRSE (mean CFU/ml ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None (control)</td>
<td>4.4 × 10&lt;sup&gt;9&lt;/sup&gt; ± 1.2 × 10&lt;sup&gt;9&lt;/sup&gt;</td>
<td>6.9 × 10&lt;sup&gt;10&lt;/sup&gt; ± 1.8 × 10&lt;sup&gt;10&lt;/sup&gt;</td>
</tr>
<tr>
<td>Rifampin&lt;sup&gt;b&lt;/sup&gt;</td>
<td>6.7 × 10&lt;sup&gt;9&lt;/sup&gt; ± 0.9 × 10&lt;sup&gt;9&lt;/sup&gt;</td>
<td>0.88 × 10&lt;sup&gt;10&lt;/sup&gt; ± 0.3 × 10&lt;sup&gt;10&lt;/sup&gt;</td>
</tr>
<tr>
<td>Rifampin + RIP&lt;sup&gt;b&lt;/sup&gt;</td>
<td>&lt;10</td>
<td>&lt;10</td>
</tr>
<tr>
<td>Rifampin + DD&lt;sub&gt;13&lt;/sub&gt;&lt;sup&gt;b&lt;/sup&gt;</td>
<td>&lt;10</td>
<td>&lt;10</td>
</tr>
<tr>
<td>Rifampin + DD&lt;sub&gt;13&lt;/sub&gt;–RIP&lt;sup&gt;b&lt;/sup&gt;</td>
<td>&lt;10</td>
<td>&lt;10</td>
</tr>
</tbody>
</table>

<sup>a</sup> Grafts presoaked in saline (control), rifampin alone (5 mg/liter), or rifampin combined with either RIP, DD<sub>13</sub>, or DD<sub>13</sub>–RIP (10 mg/liter) were implanted in rats and inoculated with MRSA or MRSE. Grafts were removed after a week and assessed for viable CFU. Detection limit, 10 CFU/ml. *, P < 0.05 compared to control untreated group.
bound amount of 27 ± 0.5 μg/cm², whereas DD13-RIP bound more than RIP but less than DD13, with a mean bound amount of 16 ± 2 μg/cm². The data indicate that longer soaking periods enabled uptake of larger amounts of each peptide. For instance, nearly 100% (i.e., 50 μg) of DD13 was found to bind after 5 h of soaking (Fig. 1). While these experiments indicate that longer soaking times result in higher peptide concentrations on the grafts, they also demonstrate that the high protective efficacy of the chimeric peptide compared to the peptides alone is not due to its relative concentration but rather to its specific activity (see below).

(ii) Bacterial growth and RNA III synthesis. To better understand the molecular mechanisms involved in the synergistic activity, the three peptides were investigated for their effect(s) in vitro on RNA III synthesis (known to be inhibited by RIP) and for bacterial proliferation (known to be inhibited by DD13). These experiments were performed by growing S. aureus cells containing an rnaIII::blaZ fusion construct in the presence of either one of the peptides. Cultures were monitored by determination of RNA III synthesis by a colorimetric method with nitrocefin as a substrate, while the peptides' effect on bacterial viability was assessed by performing CFU counts with conventional microbiological methods. The results are summarized in Fig. 2.

DD13 and DD13-RIP displayed quasipotent bactericidal activity, whereas RIP was virtually inactive (Fig. 2A). According to the broth microdilution method, DD13 and DD13-RIP exhibited MICs of 2 mg per liter for both staphylococcal strains (compared to susceptibility to rifampin, with MICs of 0.5 mg per liter for both of the organisms). RIP did not demonstrate any in vitro bactericidal activity against either of the two strains when tested at up to 128 mg per liter (data not shown).

As also shown in Fig. 2, RIP efficiently inhibited RNA III synthesis, while both DD13 and DD13-RIP appeared to be more efficient than RIP alone. However, closer inspection of the data revealed that at high peptide concentrations, most of the inhibitory activity observed was attributable to cell death. Moreover, at low peptide concentrations, where no cell death occurred, DD13 was unable to affect RNA III synthesis, unlike DD13-RIP, which displayed the highest efficacy (Fig. 2B, inset).

CD measurements. Indication of the molecular organization of the peptides in solution was obtained from CD measurements in trifluoroethanol (Fig. 3). Since the helical organization of the 13-mer dermaseptin derivative was established by nuclear magnetic resonance (37), the present study aimed at comparing detectable differences in the CD spectrum of its elongated analog (DD13-RIP) which would point to alteration(s) of the structure. For a control peptide, another 13-mer dermaseptin S4 derivative of was used, S4 (4–16), KTLKKV LKAAA, corresponding to three residues truncated from the DD13 N terminus and elongation by three residues at the C terminus. As shown in Fig. 3, whereas the control peptide displayed a typical spectrum for a random structure, both DD13 and DD13-RIP displayed typical ellipticity spectra of an α-helix as characterized by double minima at 208 and 222 nm. DD13-RIP displayed a slight increase in ellipticity signals around 222 nm, suggesting an eventual slight stabilization of the α-helix but essentially a molecular organization similar to that of DD13.

DISCUSSION

In order to prove efficacy in preventing bacterial adhesion and biofilm formation in vivo, a well-characterized experiment-
The present study also demonstrates that, like RIP, DD₁₃ is highly efficient in inhibiting staphylococcal colonization whether used alone or in combination with the conventional antibiotic. In fact, DD₁₃ was significantly more effective than RIP. The chimeric construct, however, displayed further efficiency, endowing the Dacron graft with near sterility at the lowest doses. At present, the molecular basis for this synergistic activity is not well understood, as it could result from a number of reasons. The simplest reason that comes to mind is that DD₁₃-RIP is able to express the typical properties of both building units, i.e., TRAP antagonist activity of RIP and cytolytic activity based on membrane disruption by DD₁₃. This is hypothesized because the viable CFU assays showed that RIP had no cytolytic activity and did not enhance or reduce the bactericidal activity of DD₁₃ since DD₁₃-RIP and DD₁₃ displayed equal activity.

The CD data suggested that DD₁₃ and DD₁₃-RIP have rather similar molecular organizations. On the other hand, at nontoxic concentrations, DD₁₃ was unable to affect RNA III synthesis, unlike DD₁₃-RIP, which displayed the highest inhibitory efficacy. These results suggest that the profound in vivo inhibitory activity of DD₁₃-RIP is a result of synergistic activities based on the ability of DD₁₃ to enhance RIP’s RNA III-inhibiting activity. According to our estimate, the amount of peptide present on the graft excludes the possibility that efficacy was proportional to a much higher quantity of bound peptide. For instance, while RIP and DD₁₃-RIP bound to the graft to practically the same extents (about a twofold difference), the chimeric peptide had a much higher efficacy in vivo (more than an order of magnitude). Similarly, DD₁₃ displayed the highest binding but not the highest efficacy in vivo. This indicates that the high efficacy of the chimeric peptide in vivo is not due to its relative concentration on the graft but rather to its specific activity. Taken together, these data indicate that the extreme efficacy of DD₁₃-RIP in vivo could result from its ability to launch an overwhelming attack on the target cells, with either one or both of two different mechanisms of action simultaneously.

In conclusion, we show in this paper an alternative approach to preventing device-associated infection by *S. aureus* and *S. epidermidis*, including those caused by antibiotic-resistant strains. It is probably through modulating the bacterial mechanism of communication by RIP combined with the cytotoxic effect of DD₁₃ that their pathogenesis is inhibited. We therefore postulate that RIP and DD₁₃ act in synergy by attacking bacteria simultaneously by different mechanisms. Since DD₁₃-RIP is extremely effective in preventing staphylococcal infections, our data suggest that DD₁₃-RIP could be used to coat medical devices known to be associated with staphylococcal infections.

ACKNOWLEDGMENTS

This research was supported in part by the Israel Science Foundation (grant number 387/03) and in part by Technion’s President Research Fund.

REFERENCES


